Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06606821 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06606821 · ClinicalTrials.gov record · last posted 2025-05-22

The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease

Study acronym: IDEAL-COR
StatusRecruiting
PhasePhase 4
Started2024-10-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The objective of this study is to investigate, as a proof-of-principle, long-term (52 weeks) effects of tirzepatide once-weekly vs. placebo on changes in coronary plaque composition and progression (assessed by NIRS), plaque burden (assessed by IVUS) and microvascular function (assessed by invasively measured CFR) in overweight and obese individuals with stable coronary artery disease (CAD). In addition, the objective of a baseline cross-sectional sub-study is to explore potential metabolic and cardiovascular (CV) predictors for high arteriosclerotic plaque burden in overweight and obese individuals and to establish a cohort for future research projects.

Amendment record 1 amendment on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended once since 2024-09-19. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT06606821
Lead Sponsor Tina Vilsbøll
Conditions Coronary Artery Disease, Coronary Microvascular Dysfunction, Overweight or Obesity, Stable Angina Pectoris, Chronic Coronary Artery Disease, Atherosclerosis Cardiovascular Disease
Enrollment 124 participants
Start Date 2024-10-01
Primary Completion 2027-03-20 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-22